Français

We will relentlessly pursue precision treatments for rare diseases with our novel therapeutics to enable people to live their absolute best lives.

Without Limits.

Our Focus:

Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT Syndromes, atrial fibrillation, and resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase.

Areas of Focus:

Isla Hutton

Long QT Type 3

We gain momentum everyday in our relentless pursuit of a treatment for Long QT Syndrome - In memory of Isla.

Together We Thryv


The enthusiasm of our investors is a reflection of breakthrough science, hard work and the dedication of our scientists, founders and collaborators.

Together we share a vision to transform the lives of people with life-threatening conditions.

Follow our journey